IL16 and neoplasm: Specifically, alterations in cytokines such as IL32, IL22, IL17F, IL17A, IL16, IL15, and HMGB1 [109,110] can create an immunosuppressive tumor microenvironment in CTCLs to facilitate immune evasion and tumor progression.